ClinicalTrials.gg
CompletedNCT03448172Updated Dec 4, 2018

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

A Phase 1 interventional study of [14C]PF-05221304 in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-04.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was May 2018, 8 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The purpose of the study is to characterize the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of [14C]PF-05221304 in Healthy Adult Male Subjects

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages of 18 and 45 years, inclusive.
  2. (BMI) of >= 17.5 and \<= 30.4 kg/m2
  3. Total body weight > 50 kg (110 lb).

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, allergic disease or clinical findings.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Investigational Product

    \[14C\]PF-05221304

    Drug: [14C]PF-05221304

Interventions

  • a single oral dose of \[14C\]PF-05221304 (50 mg/100 µCi liquid formulation)

06

What researchers measure

Primary outcomes

  1. Mass Balance

    Cumulative recovery of urinary, fecal, and total excretion of radioactivity over time expressed as percentage of total radioactive dose administered

    Time frame: 0-96 hr

Secondary outcomes

  1. Metabolic profiling for PF-05221304 in plasma, urine, and feces

    Percent (%) of each radiolabeled drug-related material (parent and each metabolite) will be determined in plasma, urine and feces

    Time frame: 0-96 hr

  2. Radioactivity AUClast

    Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for radioactivity

    Time frame: 0-96 hr

  3. Plasma PF-05221304 AUClast

    Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-05221304

    Time frame: 0-96 hr

  4. Radioactivity AUCinf

    Area Under the Curve From Time Zero to Extrapolated Infinite Time \[AUC (0- infinity)\] for radioactivity

    Time frame: 0-96 hr

  5. Plasma PF-05221304 AUCinf

    Area Under the Curve From Time Zero to Extrapolated Infinite Time \[AUC (0- infinity)\] for PF-05221304

    Time frame: 0-96 hr

  6. Radioactivity Cmax

    Maximum Observed Plasma Concentration (Cmax) for radioactivity

    Time frame: 0-96 hr

  7. Plasma PF-05221304 Cmax

    Maximum Observed Plasma Concentration (Cmax) for PF-05221304

    Time frame: 0-96 hr

  8. Radioactivity Tmax

    Time to Reach Maximum Observed Plasma Concentration for radioactivity

    Time frame: 0-96 hr

  9. Plasma PF-05221304 Tmax

    Time to Reach Maximum Observed Plasma Concentration for PF-05221304

    Time frame: 0-96 hr

  10. Radioactivity t1/2

    Plasma Decay Half-Life (t1/2) for radioactivity

    Time frame: 0-96 hr

  11. Plasma PF-05221304 t1/2

    Plasma Decay Half-Life (t1/2) for PF-05221304

    Time frame: 0-96 hr

  12. Number of subjects experiencing an adverse event

    Assessment by physical examinations, adverse event monitoring, clinical laboratory measurements, vital signs and ECG. Treatment-related AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity. Treatment-emergent are events between dosing with study drug and up to 28 days after that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Drug was assessed by the investigator (Yes/No). Subjects with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: Up to 28 days post dosing of IP on Day 1

07

Study locations

1 site
  • Covance Clinical Research Unit Inc.
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in May 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2018
First posted
Feb 27, 2018
StartActual
Apr 18, 2018
Primary completionActual
May 26, 2018
CompletionActual
Jun 13, 2018
Last update
Dec 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03448172
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 27, 2018
Start date
Apr 18, 2018
Primary completion
May 26, 2018
Completion
Jun 13, 2018
Last update
Dec 4, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clesacostat

Start the discussion